Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists

A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti‐diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review...

Descripción completa

Detalles Bibliográficos
Autores principales: Giorgino, Francesco, Bonadonna, Riccardo C., Gentile, Sandro, Vettor, Roberto, Pozzilli, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071744/
https://www.ncbi.nlm.nih.gov/pubmed/26787264
http://dx.doi.org/10.1002/dmrr.2775
_version_ 1782461320412528640
author Giorgino, Francesco
Bonadonna, Riccardo C.
Gentile, Sandro
Vettor, Roberto
Pozzilli, Paolo
author_facet Giorgino, Francesco
Bonadonna, Riccardo C.
Gentile, Sandro
Vettor, Roberto
Pozzilli, Paolo
author_sort Giorgino, Francesco
collection PubMed
description A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti‐diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short‐acting glucagon‐like peptide‐1 receptor agonists exenatide and lixisenatide. Current treatment guidelines will be summarized and discussed. © 2016 The Authors. Diabetes/Metabolism Research and Reviews Published by John Wiley & Sons Ltd.
format Online
Article
Text
id pubmed-5071744
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50717442016-11-02 Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists Giorgino, Francesco Bonadonna, Riccardo C. Gentile, Sandro Vettor, Roberto Pozzilli, Paolo Diabetes Metab Res Rev Review Articles A substantial proportion of patients with type 2 diabetes mellitus do not reach glycemic targets, despite treatment with oral anti‐diabetic drugs and basal insulin therapy. Several options exist for treatment intensification beyond basal insulin, and the treatment paradigm is complex. In this review, the options for treatment intensification will be explored, focusing on drug classes that act via the incretin system and paying particular attention to the short‐acting glucagon‐like peptide‐1 receptor agonists exenatide and lixisenatide. Current treatment guidelines will be summarized and discussed. © 2016 The Authors. Diabetes/Metabolism Research and Reviews Published by John Wiley & Sons Ltd. John Wiley and Sons Inc. 2016-03-30 2016-09 /pmc/articles/PMC5071744/ /pubmed/26787264 http://dx.doi.org/10.1002/dmrr.2775 Text en © 2016 The Authors. Diabetes/Metabolism Research and Reviews Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Giorgino, Francesco
Bonadonna, Riccardo C.
Gentile, Sandro
Vettor, Roberto
Pozzilli, Paolo
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
title Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
title_full Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
title_fullStr Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
title_full_unstemmed Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
title_short Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
title_sort treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071744/
https://www.ncbi.nlm.nih.gov/pubmed/26787264
http://dx.doi.org/10.1002/dmrr.2775
work_keys_str_mv AT giorginofrancesco treatmentintensificationinpatientswithinadequateglycemiccontrolonbasalinsulinrationaleandclinicalevidencefortheuseofshortactingandotherglucagonlikepeptide1receptoragonists
AT bonadonnariccardoc treatmentintensificationinpatientswithinadequateglycemiccontrolonbasalinsulinrationaleandclinicalevidencefortheuseofshortactingandotherglucagonlikepeptide1receptoragonists
AT gentilesandro treatmentintensificationinpatientswithinadequateglycemiccontrolonbasalinsulinrationaleandclinicalevidencefortheuseofshortactingandotherglucagonlikepeptide1receptoragonists
AT vettorroberto treatmentintensificationinpatientswithinadequateglycemiccontrolonbasalinsulinrationaleandclinicalevidencefortheuseofshortactingandotherglucagonlikepeptide1receptoragonists
AT pozzillipaolo treatmentintensificationinpatientswithinadequateglycemiccontrolonbasalinsulinrationaleandclinicalevidencefortheuseofshortactingandotherglucagonlikepeptide1receptoragonists

Ejemplares similares